


Stabilis



Carmustine



Tradename

Becenun	Brazil
Bicnu	Canada, Chile, Colombia, France, Great Britain, Greece, Hungary, Iran, Ireland, Mexico, Morocco, New Zealand, Peru, Romania, Spain, Switzerland, Tunisia, United States of America
Bodacler	Argentina
Carmubris	Austria, Germany, Iran
Carmustina Grey	Peru
Carmustina Perulab	Peru
Carmustine Baxter	New Zealand
Carmustine Obvius	Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Finland, France, Germany, Great Britain, Hungary, Iceland, Ireland, Luxembourg, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden
Nitrourean	Spain
Nitrumon	Belgium, Iran, Luxembourg



Stability in solutions

		0,96 mg/ml	22°C		3			146
		0,96 mg/ml	4°C		48			146
		0,1 & 0,5 mg/ml	4°C		12			1622
		0,1 > 1 mg/ml	25°C		2			1622
		0,2 mg/ml	23°C		5.5			1501
		0,2 mg/ml	4°C		48			1501
		0,96 mg/ml	4°C		24			146
		0.2 mg/ml	25°C		8			3314
		1 mg/ml	4°C		48			1622
		3,3 mg/ml	2-8°C		24			4762

PE		0,96 mg/ml	22°C		3			146
PE		0,96 mg/ml	4°C		48			146
PE		0,1 mg/ml	25°C		2			1622
PE		0,1 & 0,5 mg/ml	4°C		48			1622
PE		0,2 mg/ml	23°C		2.5			1501
PE		0,2 mg/ml	4°C		48			1501
PE		0,33 mg/ml	4°C		2			1520
PE		0,33 & 1,6 mg/ml	22°C		3			1520
PE		0,5 & 1 mg/ml	25°C		4			1622
PE		1 mg/ml	4°C		12			1622
POF		0,2 mg/ml	2-8°C		48			4762
POF		0,2 mg/ml	22°C		6			4762
POF		1 mg/ml	2-8°C		48			4762
POF		1 mg/ml	22°C		8.5			4762
POF		1 mg/ml	23°C		6			2146































Factors which affect stability

				837
				715
				837
				146
	> 30°C			3314
	3,3 < pH < 4,8			837



Compatibility

			715
			307
			3
			99

	Carmustine : 1.5 mg/ml Etoposide phosphate : 5 mg/ml		1410
	Carmustine : 1.5 mg/ml Filgrastim : 30 µg/ml		244
	Carmustine : 1.5 mg/ml Fludarabine phosphate : 1 mg/ml		492
	Carmustine : 1.5 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
	Carmustine : 1.5 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
	Carmustine : 1.5 mg/ml Melphalan : 0.1 mg/ml		169
	Carmustine : 1.5 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
	Carmustine : 1.5 mg/ml Piperacillin sodium / tazobactam : 40/5 mg/ml		81
	Carmustine : 1.5 mg/ml Sargramostim : 10 µg/ml		335
	 Carmustine : 0,1 mg/ml Sodium bicarbonate : 84 mg/ml	 	715
	Carmustine : 1.5 mg/ml Teniposide : 0.1 mg/ml		905
	Carmustine : 1.5 mg/ml Thiotepa : 1 mg/ml		249
	Carmustine : 1.5 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Route of administration



References









































	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	Journal	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.

146	Journal	Hadji-Minaglou-Gonzalvez MF, Gayte-Sorbier A, Airauto CB, Verdier M. Effects of temperature, solution composition, and type of container on the stability and absorption of carmustine. Clin Ther 1992 ; 14: 821-824.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
715	Journal	Colvin M, Hartner J, Summerfield M. Stability of carmustine in the presence of sodium bicarbonate. Am J Hosp Pharm 1980 ; 37: 677-678.
837	Journal	Fredriksson K, Lundgren P, Landersjo L. Stability of carmustine - kinetics and compatibility during administration. Acta Pharm Suec 1986 ; 23: 115-124.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1501	Journal	Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M. Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials. Int J Pharm 1999 ; 185: 113-121.
1520	Manufacturer	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1622	Journal	Favier M, De Casanove F, Coste A, Cherti N, Bressolle F. Stability of carmustine in polyvinyl chloride bags and polyethylene-lined trilayer plastic containers. Am J Health-Syst Pharm 2001 ; 58: 238-241.

2146	Journal	Trissel LA, Xu QA, Baker M. Drug compatibility with new polyolefin infusion solution containers. Am J Health-Syst Pharm 2006 ; 63: 2379-2382.
3314	Manufacturer	Carmustine (Bicnu®) – Résumé des caractéristiques du produits Bristol Myers Squibb 2011
4762	Journal	Knoll L, Kraemer I, Thiesen J. Physicochemical stability of carmustine-containing medicinal products after reconstitution and after dilution to ready-to-administer infusion solutions stored refrigerated or at room temperature EJHP 2023 ; 30, 1: 11-16.



Dictionary

 Anticancer drug	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 NaCl 0,9% or Glucose 5%	 Protect from light
 Hour	 Sodium chloride 0,9%
 Glucose 5%	 specific solvent
 Polyethylene	 Day
 Polyolefine	 Light
 Factors which affect stability	 Induces
 Degradation	 Solvent
 NaHCO ₃	 Polyvinyl chloride
 Adsorption	 Increase
 Enhanced stability	 Compatibility
 Compound	 Chemical instability
 Incompatible	 Production of gas bubbles
 Compatible	 Route of administration
 Intravenous infusion	 References
 Dictionary	